PinnyPeptide

LL-37 vs TB-500

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

LL-37

Healing & Recovery

Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity.

Peptide B

TB-500

Healing & Recovery

Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity.

Typical vial

5 mg

Typical dose

50-100 mcg

Half-life

~15-30 minutes (rapidly degraded by proteases)

FDA status

Not FDA approved for human use.

Typical vial

5 mg

Typical dose

2000-5000 mcg

Half-life

~6-8 hours

FDA status

Not FDA approved for human use.

LL-37 effects

  • Broad-spectrum antimicrobial activity against bacteria, fungi, and viruses
  • Disrupts biofilm formation
  • Promotes wound healing and angiogenesis
  • Modulates innate immune responses
  • Neutralizes bacterial endotoxins (LPS)

TB-500 effects

  • Promotes wound healing and tissue repair
  • Reduces inflammation and fibrosis
  • Stimulates new blood vessel growth
  • Supports cardiac repair after ischemic injury
  • Enhances cell migration through actin upregulation

LL-37 side effects

  • Injection site redness and irritation
  • Potential cytotoxicity at high concentrations
  • Possible mast cell activation
  • Localized skin reactions

TB-500 side effects

  • Injection site irritation
  • Temporary head rush or lightheadedness
  • Mild lethargy
  • Headache

LL-37 dosing ranges

Antimicrobial support

50-100 mcg · Once daily (SubQ) · 2-4 weeks

Wound healing support

50-100 mcg · Once daily near affected area · 2-4 weeks

TB-500 dosing ranges

Acute injury healing

2000-5000 mcg · Twice weekly · 4-6 weeks

Maintenance and recovery

2000 mcg · Once weekly · 4-8 weeks

LL-37 vs TB-500 — common questions

What is the difference between LL-37 and TB-500?

LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. TB-500: Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.

Can you stack LL-37 and TB-500?

Stacking LL-37 with TB-500 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, LL-37 or TB-500?

LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support. TB-500 is typically dosed: Twice weekly for Acute injury healing; Once weekly for Maintenance and recovery.

Are LL-37 and TB-500 FDA approved?

LL-37: Not FDA approved for human use. TB-500: Not FDA approved for human use.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free